Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
about
Purine Antagonists for Chronic Lymphocytic LeukaemiaPurine Antagonists for Chronic Lymphocytic LeukaemiaThe role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapiesThe emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaStem cell transplantation in chronic lymphocytic leukemiaFludarabine in the treatment of chronic lymphocytic leukemia: a reviewCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaOfatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association dataBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaProfile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemiaSystematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trialsSynergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine ModelCovalent and Noncovalent Intermediates of an NAD Utilizing Enzyme, Human CD38Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsThe biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemiaManagement of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitorsChronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatmentTrial Watch: Proteasomal inhibitors for anticancer therapyThe biology behind PI3K inhibition in chronic lymphocytic leukaemiaPentostatin in chronic lymphocytic leukemiaRe-directing an alkylating agent to mitochondria alters drug target and cell death mechanismIdentification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugsThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.An update on the management of chronic lymphocytic leukaemia.ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias.Alemtuzumab in chronic lymphocytic leukemiaFludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabine.Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis.Oblimersen for the treatment of patients with chronic lymphocytic leukemia.Alemtuzumab for B-cell chronic lymphocytic leukemia.Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLLSafety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
P2860
Q24245132-BECD5A6B-DCCA-482D-968C-E2994CA9A34BQ24248167-9985F402-3854-4484-B5BC-E7280B5D95CEQ24605471-0FF6A266-524A-4571-9A98-5DCE56444380Q24617708-1CBBC47F-D6EA-4CE8-B671-B962EC94BED0Q24642921-5AB04D25-9859-4D29-A01C-C92B79025BA0Q24645173-D32A07A8-9F86-4E26-A6F0-4C4A2E8738F3Q24681296-CDF9FB1D-9451-4DC1-A758-B21990C18069Q26738934-D7B5974E-04B6-4365-A6D2-648CDE88B6B0Q26765624-18B37480-698F-4EE2-9F3B-E48C81911451Q26781163-9240E9DC-716E-47B6-B83E-400E696F960FQ27001163-514C682A-B284-448A-B41C-CA82CE7843DDQ27312452-3ED2C897-749E-4F2F-8771-A90D313EB3B5Q27652605-7868DD98-D4D7-4C87-A472-974F3925A937Q28075606-096AFDF5-E46F-4C86-A8DF-EABB60D1D73AQ28075683-411D1895-50FA-455E-BFD6-FA8FD710A8F3Q28081162-75F44BD5-D913-4949-B5D3-E2BC0006BFB2Q28082086-F14B3C6B-9071-4231-94C3-3BAB0CAEE51CQ28082910-1E37753F-C536-4394-970B-D3A23B3844F6Q28083266-36EFF19C-491E-45C8-86C6-7AAC3BC69E61Q28291531-48FEC122-4C26-4E72-8F55-C6CA400D9BA9Q28486104-E2B06997-FEDF-4206-9E5D-101A2716D603Q28533669-FF70C957-3D5E-4A6D-AB21-C01929349DA1Q30243968-AB106746-5F8D-430C-A441-6A7CB77173BEQ30341946-68930AB6-8CD2-4ECC-ABA0-508A3AADDBFCQ30486336-B042617E-B023-44CA-99F1-679A1AB739B2Q31150630-31446C6F-699D-4D53-86E5-F975ABA4CC06Q33288974-03986EA9-112B-41AB-9DA9-138730144F9EQ33338763-66C5DA72-1049-47B0-87D9-9ADAF27CFC37Q33344377-2DB9430F-AAE6-4084-B0AB-FD78F5EBB6C7Q33346607-862D728D-0397-4F9C-8A54-3E9E18258900Q33347614-03A2744E-0C2A-42EC-920D-80EAD33C90A8Q33363498-7DB175C2-2DAC-47E6-B6BC-8C3A5306596AQ33379565-D48F32DB-AE1A-40AD-B36F-BC3DCFEF4FF5Q33380135-02BF3AA5-8EE3-47B7-B258-DF2E5E1CD3BCQ33391919-DCFCE87A-CB62-4DD5-91B1-DB31D23333C3Q33394947-6DCAE028-A0FD-49ED-A708-3970D0C4892FQ33397239-EC70433A-2DDF-4AD4-81C3-49146A060986Q33401132-69B7C6DB-52CC-4128-BDBD-B1221159FD5DQ33418091-6FC2B482-A4F7-4A5B-9C24-165D369A0C6CQ33438714-21484332-45BF-4B38-8AA6-389D8C41A945
P2860
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Fludarabine compared with chlo ...... r chronic lymphocytic leukemia
@ast
Fludarabine compared with chlo ...... r chronic lymphocytic leukemia
@en
Fludarabine compared with chlo ...... r chronic lymphocytic leukemia
@nl
type
label
Fludarabine compared with chlo ...... r chronic lymphocytic leukemia
@ast
Fludarabine compared with chlo ...... r chronic lymphocytic leukemia
@en
Fludarabine compared with chlo ...... r chronic lymphocytic leukemia
@nl
prefLabel
Fludarabine compared with chlo ...... r chronic lymphocytic leukemia
@ast
Fludarabine compared with chlo ...... r chronic lymphocytic leukemia
@en
Fludarabine compared with chlo ...... r chronic lymphocytic leukemia
@nl
P2093
P3181
P1476
Fludarabine compared with chlo ...... r chronic lymphocytic leukemia
@en
P2093
B D Cheson
B L Peterson
C A Schiffer
G A Threatte
L Shepherd
R A Larson
P304
P3181
P356
10.1056/NEJM200012143432402
P407
P577
2000-12-14T00:00:00Z